FDA panel rejects testosterone patch for women on safety grounds.

Ray Moynihan*

*Corresponding author for this work

Research output: Contribution to journalArticleProfessional

18 Citations (Scopus)


A panel of advisers to the US Food and Drug Administration last week unanimously rejected an experimental testosterone patch as a treatment for women with sexual difficulties.

Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.”
Original languageEnglish
Pages (from-to)1363-1363
Number of pages1
JournalBMJ (Clinical research ed.)
Issue number7479
Publication statusPublished - 11 Dec 2004


Dive into the research topics of 'FDA panel rejects testosterone patch for women on safety grounds.'. Together they form a unique fingerprint.

Cite this